Other languages BioXcel Therapeutics, Inc.

Equities

BTAI

US09075P1057

Real-time Estimate Cboe BZX Other stock markets 15:13:11 14/05/2024 BST			5-day change	1st Jan Change
2.29 ^USD	+4.81%		-4.47%	-23.90%

05-09	BioXcel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-09	Transcript : BioXcel Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioXcel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential	04-22
Bioxcel Therapeutics, Inc. Announces Transquility In-Care Pivotal Phase 3 Trial Plan with Bxcl501 for Agitation Associated with Alzheimer's Dementia	04-10
BioXcel Therapeutics Prices $25 Million Registered Direct Offering of Shares, Warrants	03-25
50 valores para invertir en IA, salud, movilidad y energía	03-25
50 aandelen om te beleggen in KI, gezondheid, mobiliteit en energie	03-23
50 titoli per investire in AI, salute, mobilità ed energia	03-22
50 Top-Aktien für Investitionen in KI, Gesundheit, Mobilität und Energie	03-22
50 valeurs pour investir dans l'IA, la Santé, la Mobilité et l'Energie	03-22
BioXcel Therapeutics Gets European Patent for Method of Treating Agitation in Dementia	03-15
BioXcel Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-12
BioXcel Therapeutics Shares Soar After Terminating Proposed $60 Million Stock Offering	02-13
BioXcel Therapeutics' BXCL701 Granted FDA Fast-Track Designation to Treat Small Cell Neuroendocrine Prostrate Cancer	02-12
BioXcel Therapeutics, Inc. Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer	02-12
Top Midday Decliners	02-09
BioXcel Therapeutics Starts $60 Million Public Offering; Shares Drop	02-09
Wall Street Set to Open Modestly Higher as S&P Hovers Just Above 5,000	02-09
Positive Quarterly Earnings Boost Exchange-Traded Funds, Equity Futures Pre-Bell Friday	02-09
US Futures Nudge Higher as S&P Remains Just Above 5,000	02-09
Top Premarket Decliners	02-09

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages BioXcel Therapeutics, Inc.

Equities

BTAI

US09075P1057

Other languages

Filters